• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Wesley Clark

    3/11/21 9:48:16 PM ET
    $NK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NK alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Clark Wesley

    (Last) (First) (Middle)
    C/O IMMUNITY, BIO, INC.
    3530 JOHN HOPKINS COURT

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/09/2021
    3. Issuer Name and Ticker or Trading Symbol
    ImmunityBio, Inc. [ IBRX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Sonja Nelson, as Attorney-in-Fact 03/11/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NK
    Leadership Updates

    Live Leadership Updates

    See more
    • Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

      FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (NASDAQ:NK) an

      6/23/21 4:05:00 PM ET
      $NK
      $MOTS
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
    • ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

      CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately. With the appointment of Messrs. Brennan and Clark, the company’s board expands to four directors, including Christobel Selecky, who was appointed to the board in August 2020, and Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio. All four directors are expected to serve on the combined board of ImmunityBio and NantKwest (Nasdaq: NK) upon completion of the pending merger. “As we exp

      2/24/21 9:00:00 AM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • ImmunityBio Appoints Fabio M. Benedetti, M.D., as Chief Strategy Officer

      CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, today announced that it has appointed Fabio M. Benedetti, M.D., as Chief Strategy Officer, effective January 4, 2021. Dr. Benedetti brings more than 20 years of biotech and large pharma experience in oncology clinical development and medical affairs. In this role, he will oversee life-cycle management, pipeline and commercial strategy, including medical affairs. Following the completion of ImmunityBio’s proposed merger with NantKwest, Dr. Benedetti is expected to assume the role of Chief Strategy Officer of the combined company. “I am pleased to welcome Fabio, a proven leader in clini

      12/30/20 9:25:00 AM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee

      FORT LAUDERDALE, Fla., June 23, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced the appointment of Sonja Nelson, CPA to the Company's Board of Directors and as Chair of the Audit Committee. Ms. Nelson brings more than 25 years of financial and operational leadership and expertise in biotechnology, diagnostics, and biopharmaceuticals markets, including playing an integral role in the successful merger between NantKwest, Inc. (NASDAQ:NK) an

      6/23/21 4:05:00 PM ET
      $NK
      $MOTS
      $IBRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
    • ImmunityBio and NantKwest Complete Merger

      CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. (“ImmunityBio”) and its shares of common stock will commence trading on NASDAQ on March 10, 2021 under the new ticker “IBRX.” “ImmunityBio is the culmination of a decades-long quest to orchestrate natural killer cells

      3/9/21 4:15:00 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stockholders of NantKwest Approve Merger With ImmunityBio

      EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special meeting of stockholders held earlier in the day, including approval of the merger by a majority of unaffiliated stockholders of NantKwest. Final voting results for NantKwest’s special meeting of stockholders will be disclosed in a Form 8-K to be filed by NantKwest with the Securities and Exchange Commission. The merger is expected to close on March 9, 2021, subject to the sa

      3/8/21 4:30:00 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by Christobel Selecky

      3 - ImmunityBio, Inc. (0001326110) (Issuer)

      3/11/21 9:50:09 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by C. David Sachs

      3 - ImmunityBio, Inc. (0001326110) (Issuer)

      3/11/21 9:49:24 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by Wesley Clark

      3 - ImmunityBio, Inc. (0001326110) (Issuer)

      3/11/21 9:48:16 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed

      SC 13D/A - ImmunityBio, Inc. (0001326110) (Subject)

      3/12/21 2:59:29 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NK
    SEC Filings

    See more
    • SEC Form 8-K filed by NantKwest, Inc.

      8-K - ImmunityBio, Inc. (0001326110) (Filer)

      3/17/21 5:24:15 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed

      8-K - ImmunityBio, Inc. (0001326110) (Filer)

      3/9/21 9:58:48 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 425 filed

      425 - NantKwest, Inc. (0001326110) (Subject)

      3/8/21 4:50:54 PM ET
      $NK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care